BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FAC...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: November 30, 2023

TEXAS DEPARTMENT OF TRANSPORTATION HONORED FOR REDUCING PEDESTRIAN FATALITIES ON AUSTIN'S I-35 • Ecolomondo Releases Its Interim Consolidated Financial Statements for the Third Quarter of 2023. Provides Amendment to Market Ma • Port Houston Second Annual Posada • Zeta Marketing Platform Surges With 64% YoY Increase in Omnichannel Marketing During Holiday Season Kickoff • Primerica Household Budget Index™: Middle-Income Households Saw Improving Financial Conditions in October • Sila Begins the Build-Out of its Moses Lake Plant for 2025 Production of Titan Silicon • IBM Advances Geospatial AI to Address Climate Challenges • MINNESOTA DEPARTMENT OF TRANSPORTATION HONORED FOR WIDESPREAD USE OF "J-TURN INTERSECTIONS" TO REDUCE SEVERITY OF CRASHES • Oceaneering Announces Release of 2023 Task Force on Climate-Related Financial Disclosures Report • SBB Research Group Foundation Names September 2023 Grant Finalists: In His Hands Resource Center, Milton Township Food Pantry, P • CALTRANS HONORED FOR ENHANCING PEDESTRIAN SAFETY AND PREVENTING WRONG-WAY DRIVING AND RUN-OFF-ROAD CRASHES • The ODP Corporation to Present at the Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference Monday, D • Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormon • FLORIDA DEPARTMENT OF TRANSPORTATION HONORED FOR FRICTION TREATMENT THAT REDUCES STOPPING DISTANCES AT INTERSECTIONS • HelloGard Welcomes Sarah Hoit to Advisory Board • LOUISIANA'S ACADIANA PLANNING COMMISSION HONORED FOR REDUCING SEVERE CRASHES AT RURAL "T" INTERSECTIONS • Groundswell Fund Announces Yamani Yansá Hernandez as Its Next CEO • Impact Podcast with John Shegerian to Feature Lineup of “ESG All-Stars” from Iconic Brands for December • Technip Energies and John Cockerill Reach Closing of Rely, a New Company Dedicated to Integrated Green Hydrogen and Power-to-X S • SOUTH JERSEY TRANSPORTATION PLANNING ORGANIZATION HONORED FOR CUMBERLAND COUNTY PLAN TO PROTECT PEDESTRIANS AND CYCLISTS

BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD

PR Newswire

SALT LAKE CITY, Sept. 28, 2023

SALT LAKE CITY, Sept. 28, 2023 /PRNewswire/ -- A new national survey from Myriad Genetics Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, revealed that breast density and family health history are two misunderstood breast cancer risk factors.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9194951-myriad-genetics-cancer-risk-survey-breast-cancer-screenings/

Of the women surveyed:

48% do not know what breast density is and 50% are unsure if it has anything to do with breast cancer risk
Few women feel like they have all the medical information they need from their mother's side (19%) and father's side (15%) to better understand their breast cancer risk
Nearly a quarter of women reported they don't talk about health issues in their families as the primary reason they don't know anything about their mother's and father's family medical history

Women with dense breast tissue are up to four times more likely to develop breast cancer compared to women without dense breasts.¹ Higher-density tissue can make it more difficult to detect breast masses or cancer during a screening and may require additional imaging tests. The Federal Drug Administration recently updated mammography regulations requiring mammography facilities to notify patients about the density of their breasts by September 2024.

More information is available here.

About Myriad Genetics Cancer Risk nationwide survey

Myriad Genetics Cancer Risk Survey is a nationwide poll conducted online by ACUPOLL Precision Research, Inc. from June 20-29, 2023 among a statistically representative sample (n=1632) of U.S. females age 18+. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.

About Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

MyRisk is the first hereditary cancer test to incorporate breast density using Tyrer-Cuzick version 8 (TCv8) and evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk. For more information, please visit: https://myriad.com/hcp-myrisk-hereditary-cancer-test/.

¹ McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–69. doi: 10.1158/1055-9965.EPI-06-0034 [PubMed] [Google Scholar]